Drug news
NICE now recommends Imnovid (pomalidomide) as a treatment for multiple myeloma- Celgene
The National Institute for Health and Care Excellence (NICE) has published draft guidance that recommends use of Imnovid (pomalidomide) (Pomalyst in the US) from Celgene to treat multiple myeloma, reversing an earlier decision. New comparative data and a discount has convinced NICE that Imnovid plus low-dose dexamethasone can be considered cost effective therapy for patients who have relapsed after three prior treatments including lenalidomide and bortezomib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins